Sins of Omission

Medical writers and editors for the general press don't intend to inflict cruelty on suffering people. But that's what they often deliver in the rote-journalism pursuit of informing the public of new developments in medical research, no matter how distant they may be from therapeutic application. News of direct health value to the public deserves the prompt coverage that it regularly receives. But not so the mere research fragments that raise unrealistic hopes, leaving distressed people empt

Written byDaniel Greenberg
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Medical writers and editors for the general press don't intend to inflict cruelty on suffering people. But that's what they often deliver in the rote-journalism pursuit of informing the public of new developments in medical research, no matter how distant they may be from therapeutic application.

News of direct health value to the public deserves the prompt coverage that it regularly receives. But not so the mere research fragments that raise unrealistic hopes, leaving distressed people empty-handed, dismayed, and uncomprehending when they rush to the doctor pleading for the help that they "saw in the paper."

Harvested from medical and scientific journals and university and corporate press-release hype, scientific scraps are routinely ingested by the news media and regurgitated in lay translation, with hopeful implications or direct assertions of progress, advances, and new treatment possibilities. That no treatment is available now, soon, or possibly ever, may or may not make ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies